Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

GNLX 12.13.2024

Full Press ReleaseSEC FilingsOur GNLX Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - HC Wainwright at Home with Genelux Corporation
  • 12.13.2024 - Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Recent Filings

  • 12.31.2024 - 4/A Statement of changes in beneficial ownership of securities
  • 12.30.2024 - 144 Report of proposed sale of securities

WESTLAKE VILLAGE, Calif.,Dec. 13, 2024(GLOBE NEWSWIRE) --Genelux Corporation(NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced thatThomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat withH.C. Wainwright & Co.onDecember 16, 2024.

Biotech Equity ResearchAnalyst,Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register athttps://ct.to/n900Z9K. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

AboutGenelux CorporationGenelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICETM platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visitwww.genelux.comand follow us on Twitter@Genelux_Corpand onLinkedIn.

Investor and Media Contacts

Ankit Bhargava, MDAllele Communications, LLCgenelux@allelecomms.com

Source:Genelux Corporation

Primary Logo

Source: Genelux Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com